Blog
RSS FeedPosted by Michael Wonder on 21 Jul 2016
Lilly’s Alimta wins NICE support
21 July 2016 - NHS use of Eli Lilly's Alimta to treat patients with lung cancer has been endorsed in final ...
Posted by Michael Wonder on 20 Jul 2016
Breakthrough lung cancer drug must be available on NHS, AstraZeneca says
20 July 2016 - A breakthrough lung cancer drug developed by UK scientists, which passed final clinical trials this week, might ...
Posted by Michael Wonder on 20 Jul 2016
NICE publishes final guidance recommending ataluren for children with Duchenne muscular dystrophy
20 July 2016 - NICE has published final guidance recommending ataluren for treating children aged 5 and over with Duchenne muscular ...
Posted by Michael Wonder on 17 Jul 2016
Londoner’s crowdfunding bid for £200,000 vital cancer drug
15 July 2016 - A young Londoner with advanced cancer today told how he turned to crowdfunding to raise £200,000 for ...
Posted by Michael Wonder on 15 Jul 2016
NICE rejects United Therapeutics’ cancer drug
15 July 2016 - NICE has rejected United Therapeutics’ Unituxin (dinutuximab) in combination therapy to treat a rare cancer affecting children ...
Posted by Michael Wonder on 12 Jul 2016
Degarelix acetate: the prostate cancer lifeline drug finally approved after three-year wait
12 July 2016 - Thousands of men suffering from advanced prostate cancer have been thrown a lifeline after a drug that ...
Posted by Michael Wonder on 12 Jul 2016
NICE draft guidance extends treatment options for thousands of people with severe rheumatoid arthritis
12 July 2016 - New draft guidance from NICE means thousands of people suffering with severe rheumatoid arthritis will have more ...
Posted by Michael Wonder on 09 Jul 2016
'Cancer drug that the NHS refuses to pay for brought me back from the dead'
9 July 2016 - Simon Lamont-Brown returned home within weeks of taking nivolumab after being given days to live in a ...
Posted by Michael Wonder on 08 Jul 2016
NHS England, PTC reach agreement on Duchenne drug
8 July 2016 - Children in England suffering from a rare form of muscular dystrophy will soon be able to access ...
Posted by Michael Wonder on 08 Jul 2016
The bottom line
8 July 2016 - t's hard to put a value on a human life. When you're well, perhaps you don't think ...
Posted by Michael Wonder on 07 Jul 2016
NICE approves first drug from old Cancer Drugs Fund
7 July 2016 - Dozens of patients with leukaemia will now have an automatic right to the drug bosutinib rather than ...
Posted by Michael Wonder on 06 Jul 2016
Charity calls on NICE to reverse Opdivo rejection
6 July 2016 - Kidney Cancer UK is calling on the National Institute for Health and Care Excellence to reverse a ...
Posted by Michael Wonder on 06 Jul 2016
Funding PrEP for HIV prevention
5 July 2016 - Delays by NHS England will cost lives—it’s time to do the right thing. ...
Posted by Michael Wonder on 05 Jul 2016
UK cost agency rejects Bristol's Opdivo for kidney cancer
5 July 2016 - Bristol-Myers Squibb's immunotherapy drug Opdivo is not worth using on the state health service for treating kidney ...
Posted by Michael Wonder on 05 Jul 2016
Unrelated future costs and unrelated future benefits: reflections on NICE Guide to the Methods of Technology Appraisal
3 July 2016 - This editorial considers the vexing issue of ‘unrelated future costs’ (for example, the costs of caring ...